Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program

This quality improvement study compares US Food and Drug Administration accelerated approvals with Canadian health and technology assessment approvals and timelines for malignant hematology and oncology treatments.

Detalles Bibliográficos
Autores principales: Ho, Cheryl, Lim, Howard J., Regier, Dean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358729/
https://www.ncbi.nlm.nih.gov/pubmed/34379128
http://dx.doi.org/10.1001/jamanetworkopen.2021.20301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358729/
https://www.ncbi.nlm.nih.gov/pubmed/34379128
http://dx.doi.org/10.1001/jamanetworkopen.2021.20301

Ejemplares similares